Protein-based therapeutics have led to new paradigms in disease treatment. Projected to be half of the top ten selling drugs in 2023, proteins have emerged as rivaling and, in some cases, superior alternatives to historically used small molecule-based medicines. This review chronicles both well-es...
Purpose of reviewProtein-based therapeutics have been applied for decades to remove most malignant tumors. Many anti-tumor drugs using antibodies have been developed and put to practical use. However, due to limitations of antibodies such as tolerance, high molecular weight, and poor tissue ...
Protein-based therapeutics have revolutionized the pharmaceutical industry and become vital components in the development of future therapeutics. They offer several advantages over traditional small molecule drugs, including high affinity, potency and specificity, while demonstrating low toxicity and minimal adv...
In principle, protein-based biotherapeutics offers a way to control biochemical processes in living cells under non-steady state conditions and with fewer off-target effects than conventional small molecule therapeutics. However, systemic protein delivery in vivo has been proven difficult due to poor ...
changes, which in turn could potentially cause protein aggregation. This study provides a systematic approach in understanding and selecting the ideal freeze–thaw conditions for manufacturing of protein-based therapeutics. It identifies the importance of balancing different excipients with an overall goal ...
a biopharmaceutical company developing a diverse pipeline of novel protein-based therapeutics, announced that the companies have entered into an exclusive partnership for the GMP manufacturing of certain of Inhibrx’s protein-based therapeutics. The agreement showcases the expansive biologics pipeline of In...
[43]. Overcoming the ECM barrier is essential for improving the survival of the high-risk group identified by our five-protein signature. Combining novel therapeutics that target TGF-β signaling/cancer-associated fibroblasts with immunotherapy would be particularly beneficial for these OC patients [44...
[43]. Overcoming the ECM barrier is essential for improving the survival of the high-risk group identified by our five-protein signature. Combining novel therapeutics that target TGF-β signaling/cancer-associated fibroblasts with immunotherapy would be particularly beneficial for these OC patients [44...
As such, GPCRs represent a significant opportunity for antibody-based therapeutics. Areas covered: The structure of the major GPCR families is summarized in the context of choice of antigen source employed in the drug discovery process and receptor biology considerations which may impact on targeting...
With the application of polymer carrier systems, therapeutics and biomolecular proteins can protect itself against the harsh environment of the gastrointestinal tract and provide efficient site-specific delivery avoiding the risk of significant side effects and immunological responses. Interests in protein-...